EUVIMEDEUVIMED entdecken
Crossref

Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity

Andrew A Renshaw, Brian J Schiro, Neeta Erinjeri, Robert Udelsman

Journal of the American Society of Cytopathology · 2024

DOI: 10.1016/j.jasc.2024.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Cytopathology, 2024. Verfasst von Andrew A Renshaw und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Baptist Hospital and Miami Cancer Institute, Miami, Florida. Electronic address: andrewr@baptisthealth.net. Hauptthemen laut MEDLINE: Thyroid Gland, Thyroid Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Previous studies suggest that the adequacy rate of thyroid aspirates can be improved by altering the adequacy criteria of the Bethesda System. We sought to measure the performance of these altered criteria in a prospective fashion. MATERIALS AND METHODS: Over a 6-year period, cases with 1 to 59 follicular cells were prospectively classified as "nondiagnostic, favor benign" or "scant but adequate". "Scant but adequate" cases were classified as either benign (Bethesda category 2) or atypia of undetermined significance (AUS) (Bethesda category 3). Bethesda category 3 cases were referred for Afirma testing (Veracyte, San Francisco, CA). RESULTS: Of 5147 cases, 131 (3%) were classified as "nondiagnostic, favor benign"; 45 (65%) of these had follow-up with a risk of malignancy of 2.6%. Additionally, 436 (8%) of all 5147 cases were classified as "scant but adequate" and "benign"; 49 (11%) of these had follow-up with a risk of malignancy of 0%. Lastly, 197 (4%) of all 5147 cases were classified as "scant but adequate" with AUS; 177 (90%) of these 197 cases had an adequate Afirma result. The "suspicious" rate was not significantly different than that of cases classified as "adequate" and AUS (Bethesda category 3 and 4) (35 of 197 [18%] versus 140 of 848 [17%] P = 0.67), and there was no significant difference in the risk of malignancy for these 2 categories ("scant but adequate" 9 of 18, "adequate" 50% versus 27 of 85, 32%, P = 0.10). Overall, the modified Bethesda criteria reduced the nondiagnostic rate from 22% to 10% (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid GlandThyroid NeoplasmsHumansBiopsy, Fine-NeedleProspective StudiesThyroid NoduleSensitivity and SpecificityFemaleMale

Stichwörter der Autor:innen

AdequacyAfirmaCytologyFine-needle aspirationMolecularThyroid

Autor:innen und Institutionen

  • Department of Pathology, Baptist Hospital and Miami Cancer Institute, Miami, Florida. Electronic address: andrewr@baptisthealth.net.
  • Department of Interventional Radiology, Baptist Hospital and Miami Cancer Institute, Miami, Florida.
  • Department of Surgery, Baptist Hospital and Miami Cancer Institute, Miami, Florida.

Zitieren

APA

Renshaw, A. A., Schiro, B. J., Erinjeri, N., & Udelsman, R. (2024). Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2024.04.005

Vancouver

Renshaw AA, Schiro BJ, Erinjeri N, Udelsman R. Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity. Journal of the American Society of Cytopathology. 2024. doi:10.1016/j.jasc.2024.04.005

BibTeX
@article{Renshaw2024,
  author = {Renshaw, Andrew A and Schiro, Brian J and Erinjeri, Neeta and Udelsman, Robert},
  title = {Modified Bethesda criteria for thyroid aspirates significantly decrease nondiagnostic rates without decreasing sensitivity},
  journal = {Journal of the American Society of Cytopathology},
  year = {2024},
  doi = {10.1016/j.jasc.2024.04.005}
}
Kostenlos starten →